Search

Your search keyword '"Department of Physiology and Biochemistry [Msida, Malta]"' showing total 2 results
Start Over Author "Department of Physiology and Biochemistry [Msida, Malta]"
2 results on '"Department of Physiology and Biochemistry [Msida, Malta]"'

1. Dual function of thalamic low-vigilance state oscillations: rhythm-regulation and plasticity

Author

Magor L. Lőrincz, William M. Connelly, Adam C. Errington, Nathalie Leresche, Régis C. Lambert, François David, Stuart W. Hughes, Vincenzo Crunelli, Department of Physiology and Biochemistry [Msida, Malta], University of Malta [Malta], Neuroscience Division [Cardiff, UK] (School of Bioscience), Cardiff University, Research Group for Cellular and Network Neurophysiology [Szeged, Hungary] (Department of Physiology, Anatomy, and Neuroscience), University of Szeged [Szeged]-Hungarian Academy of Sciences (MTA), Eccles Institute of Neuroscience [Canberra, Australia] (John Curtin School of Medical Research), Australian National University (ANU), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Vertex Pharmaceuticals [Oxford, UK], Institut de Biologie Paris Seine (IBPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Réseaux de neurones et rythmes physiopathologiques = Neuronal Networks and Physiopathological Rhythms (NPS), Neuroscience Paris Seine (NPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut de Biologie Paris Seine (IBPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut de Biologie Paris Seine (IBPS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Neuroscience and Mental Health Research Institute [Cardiff, UK] (School of Medicine), Leresche, Nathalie, Unité de neurosciences intégratives et computationnelles (UNIC), Centre National de la Recherche Scientifique (CNRS), Service de Physique Théorique (SPhT), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Neurobiologie des processus adaptatifs (NPA), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Centre de recherche en neurosciences de Lyon (CRNL), and Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
0301 basic medicine, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Thalamus, Biology, Alpha wave, Sleep, Slow-Wave, Non-rapid eye movement sleep, Article, 03 medical and health sciences, Bursting, 0302 clinical medicine, Rhythm, medicine, Animals, Humans, ComputingMilieux_MISCELLANEOUS, Neocortex, Neuronal Plasticity, General Neuroscience, [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, Eye movement, 01.06. Biológiai tudományok, 030104 developmental biology, medicine.anatomical_structure, Wakefulness, Arousal, Neuroscience, 030217 neurology & neurosurgery
Abstract

International audience; During inattentive wakefulness and non-rapid eye movement (NREM) sleep, the neocortex and thalamus cooperatively engage in rhythmic activities that are exquisitely reflected in the electroencephalogram as distinctive rhythms spanning a range of frequencies from

Published
2018
Full Text
View/download PDF

2. A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

Author

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Setric J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, and Patrinos GP

Subjects
Anticoagulants administration & dosage, Anticoagulants pharmacokinetics, Cluster Analysis, Cytochrome P-450 CYP2C9 genetics, Ethnicity genetics, Europe, Humans, Vitamin K Epoxide Reductases genetics, Warfarin administration & dosage, Warfarin pharmacokinetics, Genetic Markers, Pharmacogenetics
Abstract

Pharmacogenomics aims to correlate inter-individual differences of drug efficacy and/or toxicity with the underlying genetic composition, particularly in genes encoding for protein factors and enzymes involved in drug metabolism and transport. In several European populations, particularly in countries with lower income, information related to the prevalence of pharmacogenomic biomarkers is incomplete or lacking. Here, we have implemented the microattribution approach to assess the pharmacogenomic biomarkers allelic spectrum in 18 European populations, mostly from developing European countries, by analyzing 1,931 pharmacogenomics biomarkers in 231 genes. Our data show significant inter-population pharmacogenomic biomarker allele frequency differences, particularly in 7 clinically actionable pharmacogenomic biomarkers in 7 European populations, affecting drug efficacy and/or toxicity of 51 medication treatment modalities. These data also reflect on the differences observed in the prevalence of high-risk genotypes in these populations, as far as common markers in the CYP2C9, CYP2C19, CYP3A5, VKORC1, SLCO1B1 and TPMT pharmacogenes are concerned. Also, our data demonstrate notable differences in predicted genotype-based warfarin dosing among these populations. Our findings can be exploited not only to develop guidelines for medical prioritization, but most importantly to facilitate integration of pharmacogenomics and to support pre-emptive pharmacogenomic testing. This may subsequently contribute towards significant cost-savings in the overall healthcare expenditure in the participating countries, where pharmacogenomics implementation proves to be cost-effective., Competing Interests: The authors have declared that no competing interests exist.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results